Unorthodox Ventures
Elucid

Kelly Huang, President & CEO

Elucid

ELUCID'S STORY

Accurate clinical insights based on biology

Patients with known or suspected cardiovascular disease are at risk for deadly events like heart attacks and strokes. A peek deep inside arterial walls can be life-saving. And now it's possible. Elucid is the first and only non-invasive image analysis software that combines CT angiography and histology to quantify the amount of arterial plaque to help physicians predict the risk of heart attack or stroke well before they arise.

Based on thousands of real tissue samples and images, the system's patented algorithms quantify the plaque and help inform risk so physicians can determine patient-specific treatments. A powerful tool backed by more than 40 years of clinical research, Elucid's software has been shown to be a significantly better predictor of heart attack and stroke than legacy care pathways.

"Elucid is helping prevent heart attacks and strokes, and we're thrilled to take the next step in our journey with partners like Unorthodox Ventures to accelerate our goal to deliver unprecedented precision healthcare."

— Kelly Huang, President & CEO

OUR APPROACH

We invest in early-stage startups all around the world, often helping overseas companies open their first American offices. Click below to tell us about your work.

Contact Us →